Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;39(6):642-55.
doi: 10.1055/s-0033-1353393. Epub 2013 Aug 8.

Glanzmann thrombasthenia: state of the art and future directions

Affiliations
Review

Glanzmann thrombasthenia: state of the art and future directions

Alan T Nurden et al. Semin Thromb Hemost. 2013 Sep.

Abstract

Glanzmann thrombasthenia (GT) is the principal inherited disease of platelets and the most commonly encountered disorder of an integrin. GT is characterized by spontaneous mucocutaneous bleeding and an exaggerated response to trauma caused by platelets that fail to aggregate when stimulated by physiologic agonists. GT is caused by quantitative or qualitative deficiencies of αIIbβ3, an integrin coded by the ITGA2B and ITGB3 genes and which by binding fibrinogen and other adhesive proteins joins platelets together in the aggregate. Widespread genotyping has revealed that mutations spread across both genes, yet the reason for the extensive variation in both the severity and intensity of bleeding between affected individuals remains poorly understood. Furthermore, although genetic defects of ITGB3 affect other tissues with β3 present as αvβ3 (the vitronectin receptor), the bleeding phenotype continues to dominate. Here, we look in detail at mutations that affect (i) the β-propeller region of the αIIb head domain and (ii) the membrane proximal disulfide-rich epidermal growth factor (EGF) domains of β3 and which often result in spontaneous integrin activation. We also examine deep vein thrombosis as an unexpected complication of GT and look at curative procedures for the diseases, including allogeneic stem cell transfer and the potential for gene therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A large series of missense mutations are identified within the αIIb N-terminal β-propeller. Panel (A) is a linear representation. In light blue are domains and mutations at the interface with the β3 headpiece; in blue marine are those affecting the 7 blades; and in deep blue are those away from the interface. Mutations in green lie within the FG-GAP-G motif while that in red-brown is within a Ca2+-binding domain. Asterisks represent the same mutation found in different patients. Panels (B) and (D) are computer-drawn diagrams of the Ca2+-binding motif and the FG-GAP-G motif respectively. In (C) is a computer drawn ribbon diagram of the β-propeller domain with mutations represented as red graphical sticks. Panel (E) is a Table showing the mutation count as a function of their localization. Models were obtained using the PyMol Molecular Graphics System Version 1.3; Schrödinger LLC (www.pymol.org) and the 3vdo pdb file., The mutations are listed on the GT database (http://sinaicentral.mssm.edu/intranet/research/glanzmann).
Figure 2
Figure 2
Panel (A) is a linear representation of the four consecutive IEGF domains (in grades of green) of the β3 subunit with each mutation localized. Asterisks represent the same mutation found in different patients. Panel (B) is a computer drawn ribbon diagram of the IEGF region of β3. Mutations are represented as red graphical sticks. Models were obtained using the PyMol Molecular Graphics System, version 1.3, Schrödinger, LLC (www.pymol.org) and the 3ije pdb file.

References

    1. George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: The spectrum of clinical disease. Blood. 1990;75:1383–1395. - PubMed
    1. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118:5996–6005. - PubMed
    1. Nurden AT, Pillois X, Nurden P. Understanding the genetic basis of Glanzmann thrombasthenia: Implications for treatment. Exp Rev Hematol. 2012;5:487–503. - PubMed
    1. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004;432:59–67. - PMC - PubMed
    1. Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidirectional signalling. Annu Rev Cell Biol. 2005;21:381–410. - PubMed

Publication types

MeSH terms

Substances